In a note, Raymond James says results from 44-subject study evaluating AbbVie’s (ABBV +9.5%)
HIV med Kaletra (lopinavir/ritonavir) in COVID-19 patients failed to
deliver a benefit, the second failure for the potential indication.
Last week, the New England Journal of Medicine published the results from a 199-subject study
that showed treatment with the combo pill failed to shorten recovery
compared to standard-of-care (SOC) treatment, although patients in the
Kaletra arm experienced a shorter stay in the ICU. The mortality rate at
day 28 favored the Kaletra group, 19.2% versus 25.0%.
https://seekingalpha.com/news/3554732-abbvie-combo-hiv-med-comes-up-short-in-covidminus-19-study-raymond-james
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.